Adhera Therapeutics Appoints Trond K. Waerness to Board of Directors
Adhera Therapeutics (OTCPK: ATRX) announced the appointment of Trond K. Waerness to its Board of Directors, effective April 23, 2021. Waerness, with over two decades of pharmaceutical experience, has worked with major companies like Glaxo-Wellcome and Novartis. His expertise spans various aspects of pharmaceutical commercialization, including sales and marketing. CEO Andrew Kucharchuk expressed confidence in Waerness's ability to identify and manage new products, which could significantly aid Adhera's growth strategy. The company emphasizes the importance of operational and financial leadership in navigating future opportunities.
- Appointment of Trond K. Waerness to the Board is expected to strengthen leadership.
- Waerness brings extensive pharmaceutical experience and a successful track record.
- His network may facilitate access to new profitable assets for growth.
- Concerns about continuity and experience gaps in leadership prior to the appointment.
Baton Rouge, LA, April 23, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera Therapeutics" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce the appointment of Trond K. Waerness to the Company’s Board of Directors. Mr. Waerness, age 53, a pharmaceutical executive who has worked in the industry since 1998, with experience in all aspects of pharmaceutical commercialization. Companies include Glaxo-Wellcome, Novartis, Cornerstone Biopharma, Jobson Healthcare, Rx Sample Solutions, and MedVantx. He has held roles in sales, sales management, BD, M&A, operations, and marketing on both the manufacturer and vendor side. He as a proven track record of success in all his positions and has since 2016 founded/co-founded three successful and profitable pharma services companies that he currently oversees operations of. He received his leadership education in the Royal Norwegian Army’s officer school and his undergraduate business education at the Lundy-Fetterman School of Business at Campbell University.
“We are thrilled to welcome Trond to our Board of Directors, as he brings a wealth of operational, financial and Pharmaceutical experience to our team,” commented, Andrew Kucharchuk, Chief Executive Officer at Adhera Therapeutics. “Mr. Waerness has a distinguished track record as an extraordinary leader and an impressive skill set to help Adhera find and manage new products in the Pharmaceutical Industry. We are confident that his knowledge and extensive professional network will prove extremely valuable to Adhera Therapeutics.”
“I am excited about the opportunity to work more closely with Adhera Therapeutics, and through my vast network in the pharmaceutical industry, contribute to the Company’s goal of finding new profitable assets which will take it to the next level of growth,” commented Mr. Waerness.
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Adhera Therapeutics' actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. Adhera Therapeutics has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Adhera Therapeutics' need for, and the availability of, substantial capital in the future to fund its operations and research and development; A more complete description of these risk factors is included in Adhera Therapeutics filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Adhera Therapeutics undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
INVESTOR AND MEDIA CONTACT:
Adhera Therapeutics, INC
Andrew Kucharchuk
Chief Executive Officer
akucharchuk@adherathera.com
FAQ
What recent leadership change occurred at Adhera Therapeutics?
What experience does Trond K. Waerness bring to Adhera Therapeutics?
How might Trond K. Waerness impact Adhera Therapeutics?
What is the stock symbol for Adhera Therapeutics?
